Although cholesterol-lowering medications can reduce the risk of recurrent cardiovascular events, premature discontinuation limits effectiveness. Discontinuation rates have not been systematically reported for lipid-lowering trials.
L
ipid lowering has been shown to reduce the risk of recurrent vascular events in patients with established cardiovascular disease. 1, 2 Although prescribing rates for lipid-lowering therapy after acute myocardial infarction (MI) are high, the effectiveness of lipid-lowering therapy in routine practice is limited by low persistence or premature discontinuation of therapy after initiation. [3] [4] [5] [6] [7] [8] [9] In long-term studies, over half of patients prescribed a statin for primary or secondary prevention discontinued therapy by 4 years. 10 Reasons for discontinuation are multifactorial, involving both patient beliefs and overall health behaviors. The most commonly cited reason for discontinuation is perceived statin-induced muscle-related symptoms, although true rates of confirmed myopathy in clinical trials are low. 11, 12 Negative press stories about therapy have also been associated with increased rates of statin discontinuation and temporally associated with increased rates of cardiovascular events. 13 Less is known about discontinuation in clinical trials. While some of the reasons for discontinuation in clinical practice are not an issue in clinical trials (eg, affordability and access to medications), factors such as real and perceived side effects, trial fatigue, and loss to follow-up are challenges to adherence in clinical trials. Clinical trial participants or the study investigators responsible may also discontinue study medications for trial-related reasons, such as the need for unblinding or withdraw from trial participation. In addition, external factors, such as new guidelines, alternate therapies, and other clinical study results, can affect discontinuation rates, particularly in trials with long durations of follow-up. Beyond the impact on patient outcomes, premature discontinuation of medication in clinical trials poses challenges to interpreting study results, particularly when results of on-treatment and intention-totreat analyses differ.
IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) randomized participants to placebo+simvastatin versus ezetimibe+simvastatin within 10 days following an acute coronary syndrome (ACS), with a median follow-up of 6 years. 2 Given the long-term follow-up of participants, IMPROVE-IT provides an opportunity to study reasons for discontinuation of lipid-lowering therapy in both the short-and long-term. In addition, during the course of IMPROVE-IT, many external events occurred that were widely publicized and could have affected medication persistence. [14] [15] [16] [17] [18] [19] One study found ezetimibe discontinuation rates did increase following a US Food and Drug Administration communication about the possible link between cancer and ezetimibe (which was later disproven) from the SEAS study (Simvastatin and Ezetimibe in Aortic Stenosis). 19 Yet another demonstrated increased discontinuation after publication of the EN-HANCE trial (Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression). 20 Both of these studies were in individuals not in IMPROVE-IT; the impact in IMPROVE-IT participants has not been evaluated.
The goals of this analysis are to (1) describe patterns of and temporal trends in medication discontinuation in IMPROVE-IT, (2) compare discontinuation rates between placebo+simvastatin versus ezetimibe+simvastatin, and (3) evaluate predictors of premature study drug discontinuation.
METHODS
IMPROVE-IT was a double-blind, double-dummy, randomized trial comparing the efficacy of placebo+simvastatin versus ezetimibe+simvastatin to reduce recurrent cardiovascular events. 2 The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure. Patients were enrolled if they had been hospitalized for ACS within the preceding 10 days and had untreated LDL-C (low-density lipoprotein cholesterol) levels of 50 to 125 mg/dL or on-treatment LDL-C levels of 50 to 100 mg/dL. Patients were randomized to 40 mg of simvastatin with either ezetimibe placebo (placebo+simvastatin) or 10 mg ezetimibe (ezetimibe+simvastatin). A total of 18 144 patients were randomized and 17 706 patients initiated the study drug.
In this analysis of medication discontinuation, we assessed medication persistence among the 17 706 patients who initiated study drug (excluded 438 who did not take any doses). Premature discontinuation was defined as permanent study
WHAT IS KNOWN
• Medication discontinuation rates for lipid-lowering therapy are high in both clinical practice and randomized trials.
• In IMPROVE-IT (Improved Reduction of Outcomes:
Vytorin Efficacy International Trial), ezetimibe lowered the risk of cardiovascular events when added to statin therapy in adults with the recent acute coronary syndrome.
WHAT THE STUDY ADDS
• In IMPROVE-IT, the highest discontinuation rates were seen in the first 30 days (Kaplan-Meier rate of 73.6 per 100 person-years) and stabilized after year 1 (8.4 per 100 person-years).
• Because of prolonged follow-up, approximately half of participants in IMPROVE-IT discontinued therapy by the end of the trial.
• Addition of ezetimibe to statin therapy did not increase rates of premature discontinuation of therapy; smoking, prior revascularization, hypertension, unstable angina as presenting diagnosis, female sex, nonwhite race, and US location were associated with increased risk of premature discontinuation.
drug discontinuation not because of study completion or death. Participants were encouraged to continue study drug after cardiovascular events that occurred during the trial; data were not censored at events. Per protocol, study medication was advised to be stopped in patients who experienced a severe adverse event (eg, elevations in transaminase levels or muscle symptoms with elevated creatine-kinase levels) but could be resumed at the discretion of study investigators. Time to discontinuation was calculated as time from randomization to last pill date, stratified by early (<30 days), intermediate (30 days-1 year), or late (>1 year to trial end, up to 8.8 years) discontinuation. Enrollment occurred between October 2005 and July 2010 with follow-up through June 2014. To evaluate temporal changes in the rate of discontinuation we evaluated the crude discontinuation rate each month of the trial beginning in June 2006 when the enrollment total surpassed 1000 patients. The proportion of randomized participants who were taking study medication at the start of the month who discontinued medication by the end of the month was evaluated over time through the end of follow-up. Trends in the monthly rate of discontinuation were evaluated with a focus on the time period surrounding key external factors about simvastatin and ezetimibe.
During the course of the trial, serious muscle-related events and muscle-related complaints were evaluated as events of special interest with additional detail beyond what was collected for other serious adverse events (SAEs) and adverse events (AEs). After the results of the SEAS trial, cancer was also specifically evaluated. Reasons for discontinuation were recorded by study coordinators at follow-up visits. Data on coordinator-reported reasons for discontinuation were combined with AE and event-of-special-interest reports to create hierarchical groupings of reasons for discontinuation, as described in Table 1 . SAEs and AEs were considered drugrelated if the investigator felt the event was likely drug-related when reporting the event. Discontinuation was classified as due to serious muscle-related event, muscle-related complaint, drug-related SAE, or drug-related AE if the patient discontinued study medication within 4 months (the interval between study visits) of a drug-related event. Discontinuation was classified as due to nondrug-related AE or SAE if the patient discontinued medication within 30 days after an AE/SAE that was not considered drug-related or if the study coordinator reported discontinuation due to AE but without a corresponding AE report.
Reasons for discontinuation among all participants were evaluated by timeframe. Kaplan-Meier (KM) estimates of time to discontinuation from the day of randomization were calculated overall and then in specific time periods: <30 days, from 30 days to 1 year, and after 1 year through year 7. Though the study follow-up extended through 8.8 years for some patients, KM estimates were performed through year 7 because of decreased reliability of the estimates at the extreme of follow-up because of smaller sample size. To estimate the potential discontinuation rate had a 30-day run-in period been used, a landmark analysis was performed including only adults who had continued study medication for at least 30 days. The 7-year KM discontinuation rate starting at day 31 was then calculated for these adults. Discontinuation rates by randomized treatment arm and by region were compared using the log-rank test. After proportionality of hazards was confirmed graphically using Schoenfeld residual plots, a multivariable Cox proportional hazards model using the time to discontinuation was performed to evaluate predictors of discontinuation. This included the following variables: age, race, sex, smoking, ST-segment-elevation MI (STEMI), non-ST-segmentelevation MI (NSTEMI), prior coronary artery bypass grafting, prior percutaneous coronary intervention, history of hypertension, creatinine clearance estimated using the CockroftGault equation, baseline creatine kinase, baseline total cholesterol, body mass index, treatment arm, and region. In addition, uptitration of simvastatin to 80 mg was included as a time-updated variable. Although the exact number of medications participants were taking was not collected, the presence or absence of a medication from each of the following classes was collected at randomization: angiotensinconverting enzyme inhibitors, angiotensin receptor blockers, aspirin, β-blocker, calcium channel blocker, thienopyridine, sulfonylurea, metformin, thiazolidinedione, α-glucosidase inhibitor, meglitinide, insulin, other diabetes mellitus medication, nitrates, warfarin, diuretic, other antihypertensive, and hormone replacement therapy. The number of medications from these classes was counted and used as a surrogate for a number of medications.
Proportional hazards testing and linearity for model variables were tested, and variables were modeled using splines when the linearity assumption was not met. Patients were censored at death; patients who had not discontinued medication at the time of death were considered adherent.
IMPROVE-IT was approved by the institutional review board or ethics committee of each participating site. All participants provided written informed consent to participate. The current analyses were approved by the Duke University institutional review board with a waiver of informed consent and HIPAA authorization.
RESULTS
The median follow-up duration was 71.9 months (interquartile range 51.8-85.8 months), and 46.7% of participants discontinued study drug by the end of the trial, with a 7-year KM discontinuation rate of 50.9% (95% CI, 50.1%-51.7%). Across all participants, the discontinuation rates were highest early in the trial, with 5.9% of all subjects discontinuing medication by day 30, 13.9% discontinuing medication between day 30 and year 1, and 26.9% discontinuing medication from years 1 through 7. Corresponding KM rates were 73.6 per 100 person-years (95% CI, 69. 15, 16, 21, 22 Reasons for discontinuation by time period are described in Table 2 . Overall, participant withdrawal/ noncompliance was the most common reason for medication discontinuation throughout the study period, representing 41.2% of all discontinuation. Non-drugrelated AEs were the second most common reason (16.9%). Non-muscle-related, investigator reported, drug-related SAEs and AEs were the third most common, accounting for 8.0% of overall discontinuation and, within the first 30 days, were the most common reason after participant-initiated discontinuation. Muscle-related complaints were the fourth most common associated cause of discontinuation, representing 8.8% of all discontinuations. Figure 3 ). Figure 4 shows KM discontinuation by region. Substantial regional differences were observed in discontinuation rates (log-rank P value <0.001), with highest rates of discontinuation observed in the United States (7- .3%]). Regional differences were highest in the first 2 years of the study, after which the KM curves were generally parallel.
Predictors of discontinuation from the multivariable Cox proportional hazards model are summarized in Table 4 . Smoking, prior coronary artery bypass grafting, history of hypertension, unstable angina at qualifying event (versus STEMI or NSTEMI), female sex, nonwhite race, and being in the United States were all associated with higher rates of discontinuation. Until the age of 65 years, increasing age was associated with higher discontinuation rates; after age 65 years, age was associated with lower discontinuation rates. The associations between baseline labs-including baseline aspartate transaminase, alanine transaminase, creatine phosphokinase, and LDL-C-and risk of discontinuation were nonlinear. Uptitration to simvastatin 80 mg (done for those with LDL-C >79 mg/dL) was associated with an increased risk of medication discontinuation. Although in the univariable analysis the rate of discontinuation differed by treatment arm, in a multivariable analysis adjusting for statin uptitration there was no statistically significant difference in discontinuation by treatment arm. While there were multiple factors statistically significantly associated with premature discontinuation, the C statistics for the multivariable model was 0.60, suggesting the poor overall ability to predict discontinuation based on clinical and laboratory parameters at baseline. 
Subject initiated
From study coordinator report, including failure to comply with protocol, subject request, did not want to take 3 pills/noncompliance, withdrew consent, subject insisted to know LDL, subject did not reconsent.
Loss to follow-up From study coordinator report, including subject moved, other loss to follow-up.
Physician initiated
From study coordinator report, including physician-directed, need for prohibited medications.
LDL >100 mg/dL Per study protocol.
Other possible side effect, not AE From study coordinator report, including study coordinator report of myalgia, elevated liver function test, or elevated creatine phosphokinase without AE/SAE report within timeframe evaluated.
Other Study coordinator report of other reason for medication discontinuation.
AE indicates adverse event; CK, creatine kinase; LDL, low-density lipoprotein; MRC, muscle-related complaint; SAE, serious adverse event; and SMRE, serious muscle-related event.
DISCUSSION
In IMPROVE-IT, discontinuation rates were highest early in the trial but decreased and stabilized after year 1. This stabilization occurred despite significant outside factors potentially affecting medication persistence and trial participation. Efforts taken to counter these influences are believed to have contributed to the maintenance of the stabilized discontinuation rate. 23 This included riskbased monitoring for patients at risk of discontinuation (eg, those missing study visits) and ongoing communication with sites to address participant retention and concerns raised from external events. Although discontinuation rates in IMPROVE-IT were similar to those in other trials, because of the length of follow-up, the cumulative rate of discontinuation after year 1 was substantial, with half of participants in IMPROVE-IT discontinuing therapy by the end of the trial. Discontinuation of study medication in IMPROVE-IT did not appear to affect the trial findings that ezetimibe+simvastatin led to reduced event rates, with efficacy seen in both the on-treatment and intention-to-treat analyses. The efficacy estimate was greater among those who continued therapy. 24 Comparing discontinuation rates in IMPROVE-IT with other lipid-lowering trials is challenged by the lack of consistent reporting of medication discontinuation rates in other trials and variable duration of follow-up. When compared with available data, discontinuation rates in IMPROVE-IT (20 per 100 personyears at year 1 and then 8.4 per 100 person-years from years 2-7) mirror those that have been reported in other trials involving statin therapy. 25 In the JUPITER trial (Justification for the Use of Statin in Prevention: An Intervention Trial Evaluating Rosuvastatin) comparing rosuvastatin with placebo, 25% of participants had discontinued therapy by study termination (median follow-up 1.9 years, and maximum follow-up 5 years), in spite of a 4-week run-in phase. 26 The PROVE IT-TIMI 22 study (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction) randomized patients after ACS hospitalization (similar to IMPROVE-IT, also a post-ACS trial) to pravastatin or atorvastatin. At 1 year, discontinuation rates were 21.4% for pravastatin and 22.8% for atorvastatin, compared with 20% at 1 year in IMPROVE-IT. 27 Discontinuation rates in the A to Z trial (high-versus low-dose simvastatin) were 34% and 32%, respectively, by the end of the trial, which had a median follow-up of <2 years. 28 Discontinuation rates reported in nonstatin lipid-lowering clinical trials vary but range from 2.5% to 19.7% at 6 months, 2.0% to 16.1% at 1 year, and up to 48.7% at 2 years. 27 Fewer long-term cardiovascular outcomes trials are available for comparison. Estimating anticipated medication discontinuation rates is an important factor in clinical design, and comparison with other trials after completion may be facilitated if future clinical trials report not just overall discontinuation by study end, but annualized discontinuation rates over the follow-up period.
The IMPROVE-IT trial faced unique challenges for patient retention. Negative results from the ENHANCE and ARBITER 6-HALTS study, which tested the efficacy of ezetimibe to reduce carotid intima-media thickness, led to widespread calls for decreased utilization of ezetimibe. 15, 17, 29 In addition, safety concerns from secondary analyses of the SEAS trial and subsequent Food and Drug Administration guidance to limit the use of simvastatin 80 mg were also covered widely in the lay press. 18 A study of pharmacy claims found that monthly ezetimibe discontinuation rates more than doubled, from <5% to nearly 10% per month in the time period after the 2008 Food and Drug Administration communication. Many clinical trials opt for a run-in period to identify participants who cannot tolerate or choose to discontinue therapy early to minimize the effect of discontinuation early in the trial. In IMPROVE-IT, to treat patients soon after the index ACS event, randomization occurred immediately without a run-in phase. Based on discontinuation rates among those who were still on medication at day 30, we conclude that including a 30-day run-in phase would not have substantially altered overall discontinuation through the duration of the study. Had those who discontinued therapy by day 30 been excluded from the trial, the overall 7-year KM discontinuation rate would have decreased from 50.9% to 47.8%. Thus, run-in periods are likely much more impactful in trials with shorter follow-up.
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In IMPROVE-IT, the rates of AEs in the placebo+ simvastatin versus the ezetimibe+simvastatin groups were similar, highlighting the safety of ezetimibe when added to statin therapy. 2 Similarly, we did not find that adding ezetimibe to simvastatin led to reduced medication persistence. In fact, the discontinuation rate at 7 years in the placebo+simvastatin arm was slightly higher than that in the ezetimibe+simvastatin treatment arm. This difference was likely driven by the higher rate of uptitration of simvastatin in the placebo+simvastatin group compared with the ezetimibe+simvastatin group (19.1% versus 14.5%). Simvastatin uptitration was associated with an increased risk of discontinuation; after adjusting for uptitration, differences in discontinuation rates in the 2 treatment arms were not statistically significantly different.
Large clinical trials are increasingly multinational; the IMPROVE-IT trial enrolled patients from 30 coun- Categorical variables presented as n (%); continuous variables presented as median (interquartile range).
ALT indicates alanine transaminase; AST, aspartate transaminase; CABG, coronary artery bypass graft; CPK, creatinine phosphokinase; LDL, low-density lipoprotein; NSTEMI, non-ST-segment-elevation myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST-segment-elevation myocardial infarction. All lab values were collected at baseline. *Medication number was assessed by counting the presence or absence of up to 12 classes of medications, as described in the methods. tries. While this allows for large sample sizes and external generalizability, reporting of intercountry variability in effect estimates is also increasingly common. 30 Although there was no statistically significant difference in the effect estimate for the primary end point by region in IMPROVE-IT, regional differences in medication persistence were substantial, with the highest discontinuation rates in the United States. This may reflect higher rates of concerns about safety of lipid-lowering therapy, higher rates of perceived side effects in the United States compared with other regions, or other differences in the health system structure in the United States, including higher out-of-pocket costs for nonstudy-related medications compared with countries with universal health care. Higher rates of discontinuation in US participants is not unique to IMPROVE-IT; the TOPCAT trial (Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist) also found regional variability in medication persistence, with 21.7% of US participants compared with 7.3% of those in Russia and Georgia discontinuing therapy. 31 Differential adherence and persistence by region has potential implications for analyses of the treatment effect and should be part of ongoing trial monitoring in large multinational trials. Despite the differences in discontinuation seen in IMPROVE-IT, no statistically significant differences were observed in effect estimates by region. 2 Despite identifying multiple risk factors for discontinuation, characteristics of patients at baseline were not sufficient to accurately predict who would discontinue medication. The fact that there was no difference in persistence between patients who entered statin-naïve versus those who were on prior therapy further implicates behavioral, cultural, or perceptual drivers of discontinuation rather than physical or drug-related intolerances. Heterogeneity in reasons for discontinuation-including physician-directed reasons, patient noncompliance, and perceived side effects-likely will prevent the development of a robust model to predict those most likely to discontinue medication. Certain patterns did emerge, with patients at highest risk for discontinuation, including women, smokers, those with unstable angina, and nonwhites, along with the region of enrollment. Patients who presented with STEMI were least likely to discontinue medication, potentially because of the increased severity of their presenting event compared with those who presented with unstable angina or NSTEMI.
Although discontinuation rates in IMPROVE-IT are similar to what has been seen in other trials, there exists room for improvement in patient retention and medication persistence. In addition, while this study focused on medication persistence, suboptimal implementation of the prescribed dosing regimens (poor adherence) also limits medication effectiveness and is closely related to persistence. Novel approaches for improving both implementation of the dosing regimen and maintaining long-term persistence, including interdisciplinary team approaches, systems changes to monitor and provide feedback, digital devices, patient reminders, and collection of patient-reported outcomes to increase patient engagement, should be considered in future trial designs.
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Strengths and Limitations
This analysis has a number of strengths, including a prospective collection of reasons for discontinuation, prolonged duration of follow-up, and lack of a runin period to allow for more generalizability to routine practice. We do acknowledge several limitations. We relied mainly on study coordinator report of reasons for discontinuation. The prespecified list prevented capture of multifactorial causes of discontinuation and may not have reflected the patient's true reason for discontinuing the study or study medication. Other factors potentially associated with discontinuation were not assessed. For example, while medication burden was estimated by using the number of medications from prespecified classes of interest, the exact number of medications participants were taking was not collected. In addition, patient polymorbidity and functional status were not assessed on all patients and may play a role in medication and trial persistence. Next, we relied on site C index=0.60 (time-dependent covariates not included). BMI indicates body mass index; CABG, coronary artery bypass graft; CPK, creatinine phosphokinase; CrCl, creatinine clearance; HR, hazard ratio; LCL, lower confidence limit; NSTEMI, non-ST-segment-elevation myocardial infarction; STEMI, ST-segment-elevation myocardial infarction; and UCL, upper confidence limit.
*Variables measured at randomization. †Continuous variables are scaled for increased interpretability. For example, the hazard of discontinuation is increased by about 44% for a subject that is 75 vs 65 y old. The scaling units are provided for each variable in the label. When the relationship between continuous variables and outcomes was nonlinear, 2-part linear splines were used to describe the relationship.
‡Categorical variables have interpretation for each level as compared with a reference group. For example, a subject from Western Europe has about 17% less hazard for discontinuation compared with a subject from the United States.
investigator determinations of whether or not the AEs were because of study drug, which may not accurately represent causality. Future trial designs may consider assessing patient-reported reasons for discontinuation as part of a comprehensive approach to understanding medication persistence in clinical trials. In addition, this analysis only included patients who permanently stopped taking study drug and not those who temporarily stopped but resumed medication. Finally, differences in the duration of follow-up in certain groups may have affected observed differences in discontinuation rates. Because discontinuation rates were highest in the first year after enrollment, groups with longer follow-up overall would have the lowest KM discontinuation rates. For example, patients with STEMI were included only in the first part of the trial, and enrollment for STEMI was capped. Therefore, STEMI patients on average had longer follow-up than NSTEMI or unstable angina patients. Similarly, differences in timing of enrollment by region may have affected overall discontinuation rates by region. However, the 2 regions with highest discontinuation-Western Europe and the United States-were also 2 of the first regions to enroll.
Conclusions
Overall discontinuation rates in the IMPROVE-IT trial were consistent with those seen in other trials. Although the highest rates of discontinuation were observed in the first year, because of the duration of the trial, most discontinuation occurred after the first year of the study. As a result, adding a run-in period to the study would not have dramatically changed observed discontinuation rates. Geographic differences in discontinuation rates were significant and should be considered when assessing regional variation in treatment effect. Adding ezetimibe to statin therapy did not increase the risk of discontinuation. Certain groups were at higher risk for medication discontinuation, including women, smokers, nonwhite participants, patients with a diagnosis of unstable angina or prior revascularization, and those in the United States. These groups should be targeted for interventions to improve medication persistence at follow-up.
